Skip to main content
Top
Published in: International Journal of Hematology 1/2019

01-01-2019 | Progress in Hematology

Molecular pathogenesis of leukemia and leukemic stem cells (LSCs)

Author: Masahiro Kizaki

Published in: International Journal of Hematology | Issue 1/2019

Login to get access

Excerpt

The 79th Annual Meeting of the Japanese Society of Hematology (JSH) was held over a 3-day period from Friday, October 20 to Sunday, October 22, 2017. This meeting was the first time in 18 years that the congress was held in Tokyo. Recent years have seen dramatic advances in hematology. Advances in basic research, mainly molecular biology and stem cell research, have enabled the identification of the molecular pathogenesis of leukemia, and the introduction of new therapeutic methods based on these discoveries has greatly transformed the clinical management of leukemia. As a president of the annual meeting, I selected “Innovation and Creation: Advances in Hematology for the Next Generation” as the theme of the congress. “Innovation and Creation” are important topics that are now required of us in studying the development of hematology. In addition, internationalization and the focus on the young generation have been the most important missions of the JSH. Therefore, along with this theme, I organized a Presidential Symposium with the title “Young Japanese Hematologists in the World: Molecular Pathogenesis of Leukemia and Leukemic Stem Cells (LSCs)”; in this symposium, five young Japanese researchers who are active on the global stage, individuals who serve as principal investigators (PIs) with their own laboratories discussed the molecular pathogenesis of leukemia and leukemic stem cells. I am sure that these enthusiastic presentations by successful young researchers from the global front lines echoed in the hearts of the younger generation in Japan. To commemorate this exciting symposium, I invited four speakers from congress to review their topics in the session of the “Progress in Hematology” in this issue of the International Journal of Hematology (IJH). …
Literature
1.
go back to reference Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7:105–17.CrossRefPubMed Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7:105–17.CrossRefPubMed
2.
go back to reference Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–71.CrossRefPubMedPubMedCentral Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–71.CrossRefPubMedPubMedCentral
4.
go back to reference Sanda T, Leong WZ. TAL1 as a master oncogeneic transcription factor in T-cell acute lymphoblastic leukemia. Exp Hematol. 2017;53:7–15.CrossRefPubMed Sanda T, Leong WZ. TAL1 as a master oncogeneic transcription factor in T-cell acute lymphoblastic leukemia. Exp Hematol. 2017;53:7–15.CrossRefPubMed
5.
go back to reference Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059–64.CrossRefPubMed Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059–64.CrossRefPubMed
6.
go back to reference Radmaska HS, Jernigan F, Nakayama S, Jorge SE, Sun L, Tenen DG. at al. J Biomol Screen. 2015;20:1150–9.CrossRef Radmaska HS, Jernigan F, Nakayama S, Jorge SE, Sun L, Tenen DG. at al. J Biomol Screen. 2015;20:1150–9.CrossRef
7.
10.
go back to reference Yoshimoto M, Montecino-Rodriguez E, Ferkowicz MJ, Porayette P, Shelley WC, Conway SJ, et al. Embryonic day 9 yolk sac and intra-embryonic hemogenic endothelium independently generate a B-1 and marginal zone progenitor lacking B-2 potential. Proc Natl Acad Sci USA. 2011;108:1468–73.CrossRefPubMedPubMedCentral Yoshimoto M, Montecino-Rodriguez E, Ferkowicz MJ, Porayette P, Shelley WC, Conway SJ, et al. Embryonic day 9 yolk sac and intra-embryonic hemogenic endothelium independently generate a B-1 and marginal zone progenitor lacking B-2 potential. Proc Natl Acad Sci USA. 2011;108:1468–73.CrossRefPubMedPubMedCentral
11.
go back to reference Yoshimoto M, Porayette P, Glosson NL, Conway SJ, Carlesso N, Cardoso AA, et al. Autonomous murine T-cell progenitor production in the extra-embryonic yolk sac before HSC emergence. Blood. 2012;119:5706–14.CrossRefPubMedPubMedCentral Yoshimoto M, Porayette P, Glosson NL, Conway SJ, Carlesso N, Cardoso AA, et al. Autonomous murine T-cell progenitor production in the extra-embryonic yolk sac before HSC emergence. Blood. 2012;119:5706–14.CrossRefPubMedPubMedCentral
Metadata
Title
Molecular pathogenesis of leukemia and leukemic stem cells (LSCs)
Author
Masahiro Kizaki
Publication date
01-01-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2550-z

Other articles of this Issue 1/2019

International Journal of Hematology 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine